Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

164P - Immune modulatory functions of lurbinectedin in small cell lung cancer and malignant pleural mesothelioma patients


03 Apr 2022


Poster Display session


Translational Research

Tumour Site

Small Cell Lung Cancer;  Mesothelioma


Luca Cantini


Annals of Oncology (2022) 33 (suppl_2): S105-S110. 10.1016/annonc/annonc865


L. Cantini1, D. Dumoulin1, M. Vink1, L. Klaase1, K. Slooff1, R. Cornelissen2, J. Mankor1, A.C. Dingemans3, M. Willemsen1, J.G. Aerts1

Author affiliations

  • 1 Erasmus MC Cancer Institute, Rotterdam/NL
  • 2 Erasmus MC Cancer Institute, 3015 CE - Rotterdam/NL
  • 3 Erasmus MC - University Medical Center, Rotterdam/NL


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 164P


Lurbinectedin (Lur) is currently investigated in pre-treated patients (pts) with small cell lung cancer (SCLC) or malignant pleural mesothelioma (MPM). According to pre-clinical models, lur has the ability to induce anticancer immune responses. The immune-modulatory functions of lur in thoracic cancer pts have not been investigated yet.


SCLC and MPM pts treated with lurbinectedin in the context of a named patient program at the Erasmus Medical Center, Rotterdam, NL were prospectively included. Comprehensive immune cell profiling by multicolor flow-cytometry was performed on screening and on treatment (after 2 cycles) peripheral blood samples.


In total, 95 pts (43 SCLC and 52 MPM) were treated, mainly as ≥3-line of therapy. In the SCLC cohort, median (m) PFS was 1.5 months (95% CI: 1.4–3.0), and mOS was 7.0 months (95% CI: 4.7–not reached). In the MPM cohort, mPFS was 2.8 months (95% CI: 1.4–4.2), and mOS was 7.2 months (95% CI: 5.9–not reached). Immunological phenotyping was performed on 39 pts. Lur significantly reduced HLADR+CD56-CD14+CD16- cell frequencies, the classical monocyte subset, in both SCLC and MPM pts. SCLC pts with lower frequencies of classical monocytes before treatment also had a longer PFS. Lur significantly increased proliferation of CD4+, CD8+ T-cells (SCLC), and NK- and NKT-cells (SCLC and MPM). Treatment increased the proliferation of CD4+ central memory (TCM) and effector memory (TEM) T-cells and of CD8+ TEM cells among SCLC. In MPM, treatment increased more specifically the proliferation of CD4+ TEM cells, while CD8+ T-cells were not affected. Finally, lur induced a two-side alteration of the circulating T-cell phenotype, with upregulation of co-stimulatory receptors being counterbalanced by upregulation of co-inhibitory markers.


Lur confirms clinical activity in pre-treated SCLC and MPM pts. Our exploratory immunomonitoring study also shows that lur might have immune-modulatory functions through depletion of the classical monocyte subset, promotion of proliferation and phenotype shifting of anti-tumor immune cell populations. Therefore, lur might represent an interesting chemotherapy backbone for future immunotherapy combinations in SCLC and MPM.

Legal entity responsible for the study

The authors.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.